Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between February 26 and February 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard E. Lowenthal, the President and CEO of ARS Pharmaceuticals, Inc. (SPRY), reported the sale of common stock in a Form 4 filing with the SEC.
• The transactions occurred on February 26 and February 28, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• On February 26, 2024, Lowenthal sold 100 shares at $9.01 per share directly, and indirectly sold 100 shares at $9.01 per share through each of the Richard E. Lowenthal Charitable Remainder UniTrust and the Sarina Tanimoto Charitable Remainder Unitrust.
• On February 26, 2024, Lowenthal indirectly sold 500 shares at $9.01 per share through the Lowenthal-Tanimoto Family Trust.
• On February 28, 2024, Lowenthal sold 25,456 shares at a weighted average price of $9.0205, 49,019 shares at a weighted average price of $9.0212, and 24,303 shares at a weighted average price of $9.0205.
• These sales were executed through various entities including direct holdings, charitable trusts, and a family trust.
• Following these transactions, Lowenthal directly owns 4,126,822 shares of common stock.
• Lowenthal also has indirect ownership through several trusts, including 1,747,294 shares via the Richard E. Lowenthal Charitable Remainder UniTrust, 2,050,481 shares via the Lowenthal-Tanimoto Family Trust, 1,748,447 shares via the Sarina Tanimoto Charitable Remainder UniTrust, and 3,276,854 shares by spouse.
• The filing indicates that Lowenthal disclaims beneficial ownership of securities held by the Sarina Tanimoto Charitable Remainder Unitrust.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock sales by an insider. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency regarding the transactions of company insiders. The use of a 10b5-1 trading plan is a common practice that allows insiders to sell shares over a period of time while avoiding concerns about insider trading.

Stakeholder Impact

• The stock sales by the CEO could be perceived negatively by some shareholders, potentially leading to a slight decrease in stock price, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates